Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Incidence and Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial.

Blood (2009) 114 (22): 2609.

https://doi.org/10.1182/blood.V114.22.2609.2609

Published: 2009

Journal Articles

Real-Time Quantitative PCR (RQ-PCR) Detection of Minimal Residual Disease (MRD) by Optimized WT1 Assay To Enhance Risk Stratification in Acute Myeloid Leukemia (AML): A European LeukemiaNet Study.

Blood (2007) 110 (11): 542.

https://doi.org/10.1182/blood.V110.11.542.542

Published: 2007

Journal Articles

The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors.

Blood (2007) 110 (11): 722.

https://doi.org/10.1182/blood.V110.11.722.722

Published: 2007

Journal Articles

Prognostic Relevance of Cytometric Quantitative Assessment in Patients with Myelodysplastic Syndromes.

B. Pollio, M.M. Ciriello, A. Fruttero, M. Geuna, A. Iavarone, P. Omede’, M. Pautasso, A.M. Pollono, A. Santagostino, G. Garbaccio Ioria, A. Stacchini, D. Gioia, D. Ferrero, F. Marmont, A. Gallamini, G. Saglio, Alessandro Levis, M. Girotto

Blood (2006) 108 (11): 2621.

https://doi.org/10.1182/blood.V108.11.2621.2621

Published: 2006

Journal Articles

High Levels of Tumor Load Reduction after Intensive Chemotherapy Favorably Affect the Prognosis of BCR/ABL+ ALL Adult Patients Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

G. Cimino, MD, L. Elia, PhD, Fabrizio Pane, MD, M. Vignetti, MD, P. Fazi, MD, S. Iacobelli, PhD, G. Meloni, MD, A. Vitale, MD, V. Martini, MD, G. Martinelli, MD, F. Di Raimondo, MD, M. Bonifacio, MD, F. Fabbiano, MD, G. Saglio, MD, M. Baccarani, MD, R. Foà, MD, F. Mandelli, MD

Blood (2006) 108 (11): 638.

https://doi.org/10.1182/blood.V108.11.638.638

Published: 2006

Journal Articles

Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.

Ilaria Iacobucci, Giovanni Martinelli, M. Amabile, A. Poerio, S. Soverini, F. Castagnetti, S. Colarossi, A. Gnani, N. Testoni, M. Breccia, E. Abruzzese, B. Martino, D. Cilloni, G. Saglio, F. Pane, G. Rosti, M. Baccarani

Blood (2006) 108 (11): 2156.

https://doi.org/10.1182/blood.V108.11.2156.2156

Published: 2006

Journal Articles

Prognostic Impact of Genetic Characterization in the GIMEMA LAM99P Study for Newly Diagnosed Adult AML. Relevance of Combined Analysis of Conventional Karyotyping, FLT3 and NPM Mutational Status.

Blood (2005) 106 (11): 226.

https://doi.org/10.1182/blood.V106.11.226.226

Published: 2005

Journal Articles

Sensitive Detection of FIP1L1-PDGFRA Fusion Transcripts by Real-Time Quantitative RT-PCR (RQ-PCR) Reveals Achievement of Molecular Remission in Chronic Eosinophilic Leukemia Treated with Low-Dose Imatinib Therapy.

Blood (2005) 106 (11): 483.

https://doi.org/10.1182/blood.V106.11.483.483

Published: 2005

Journal Articles

Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

G. Cimino, MD, L. Elia, PHD, G. Meloni, MD, L. Annino, MD, A. Chiarenza, MD, G. Martinelli, MD, F. Pane, MD, M. Montanaro, MD, P. Chiusolo, MD, A. Santoro, MD, M. Offidani, MD, M. Vignetti, MD, G. Saglio, MD, M. Baccarni, MD, F. Mandelli, MD, Robert Foa, MD

Blood (2004) 104 (11): 1082.

https://doi.org/10.1182/blood.V104.11.1082.1082

Published: 2004

Journal Articles

Definition of RAEB-I and RAEB-Ii According to the Who Classification of Myelodysplastic Syndromes (MDS): Problems Emerging from a Large Multicenter Registry.

Blood (2004) 104 (11): 1432.

https://doi.org/10.1182/blood.V104.11.1432.1432

Published: 2004

Journal Articles

Association of Kaposi's Sarcoma-Associated Herpesvirus-Positive Primary Effusion Lymphoma With Expression of the CD138/Syndecan-1 Antigen

G. Gaidano, A. Gloghini, V. Gattei, M.F. Rossi, A.M. Cilia, C. Godeas, M. Degan, T. Perin, V. Canzonieri, D. Aldinucci, G. Saglio, A. Carbone, A. Pinto

Blood (1997) 90 (12): 4894–4900.

https://doi.org/10.1182/blood.V90.12.4894

Published: 1997

Journal Articles

Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) [see comments]

F Pane, F Frigeri, M Sindona, L Luciano, F Ferrara, R Cimino, G Meloni, G Saglio, F Salvatore, B Rotoli

Blood (1996) 88 (7): 2410–2414.

https://doi.org/10.1182/blood.V88.7.2410.bloodjournal8872410

Published: 1996

Journal Articles

Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis

G Saglio, F Pane, E Gottardi, F Frigeri, MR Buonaiuto, A Guerrasio, D de Micheli, A Parziale, MN Fornaci, G Martinelli, F Salvatore

Blood (1996) 87 (3): 1075–1080.

https://doi.org/10.1182/blood.V87.3.1075.bloodjournal8731075

Published: 1996

Journal Articles

Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin‧s lymphoma

P Ballerini, G Gaidano, JZ Gong, V Tassi, G Saglio, DM Knowles, R Dalla-Favera

Blood (1993) 81 (1): 166–176.

https://doi.org/10.1182/blood.V81.1.166.166

Published: 1993

Journal Articles

BCR-ABL breakpoint and prognosis in chronic myeloid leukemia [letter; comment]

M Baccarani, G Saglio, A Zaccaria, S Tura

Blood (1992) 79 (9): 2499–2500.

https://doi.org/10.1182/blood.V79.9.2499.2499

Published: 1992

Journal Articles

New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia

G Saglio, A Guerrasio, C Rosso, A Zaccaria, A Tassinari, A Serra, G Rege- Cambrin, U Mazza, F Gavosto

Blood (1990) 76 (9): 1819–1824.

https://doi.org/10.1182/blood.V76.9.1819.1819

Published: 1990

Journal Articles

Alternative BCR/ABL transcripts in chronic myeloid leukemia [letter; comment]

A Zaccaria, A Tassinari, N Testoni, F Lauria, S Tura, R Algeri, A Guerrasio, C Rosso, G Saglio

Blood (1990) 76 (8): 1663–1665.

https://doi.org/10.1182/blood.V76.8.1663b.1663b

Published: 1990

Journal Articles

Molecular characterization of hereditary persistence of fetal hemoglobin in a patient from Cuba [letter]

G Martinez, A Hernandez, L Corral, A Muniz, C Alaez, A Serra, A Alfarano, G Saglio, C Camaschella

Blood (1990) 76 (6): 1262–1263.

https://doi.org/10.1182/blood.V76.6.1262.1262

Published: 1990

Journal Articles

Prenatal diagnosis of fetal hemoglobin Lepore-Boston disease on maternal peripheral blood

C Camaschella, A Alfarano, E Gottardi, M Travi, P Primignani, F Caligaris Cappio, G Saglio

Blood (1990) 75 (11): 2102–2106.

https://doi.org/10.1182/blood.V75.11.2102.2102

Published: 1990

Journal Articles

A new hereditary persistence of fetal hemoglobin deletion has the breakpoint within the 3' beta-globin gene enhancer

C Camaschella, A Serra, E Gottardi, A Alfarano, D Revello, U Mazza, G Saglio

Blood (1990) 75 (4): 1000–1005.

https://doi.org/10.1182/blood.V75.4.1000.1000

Published: 1990

NARROW

Incidence and Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial.

Real-Time Quantitative PCR (RQ-PCR) Detection of Minimal Residual Disease (MRD) by Optimized WT1 Assay To Enhance Risk Stratification in Acute Myeloid Leukemia (AML): A European LeukemiaNet Study.

The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors.

Prognostic Relevance of Cytometric Quantitative Assessment in Patients with Myelodysplastic Syndromes.

High Levels of Tumor Load Reduction after Intensive Chemotherapy Favorably Affect the Prognosis of BCR/ABL+ ALL Adult Patients Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.

Prognostic Impact of Genetic Characterization in the GIMEMA LAM99P Study for Newly Diagnosed Adult AML. Relevance of Combined Analysis of Conventional Karyotyping, FLT3 and NPM Mutational Status.

Sensitive Detection of FIP1L1-PDGFRA Fusion Transcripts by Real-Time Quantitative RT-PCR (RQ-PCR) Reveals Achievement of Molecular Remission in Chronic Eosinophilic Leukemia Treated with Low-Dose Imatinib Therapy.

Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

Definition of RAEB-I and RAEB-Ii According to the Who Classification of Myelodysplastic Syndromes (MDS): Problems Emerging from a Large Multicenter Registry.

Association of Kaposi's Sarcoma-Associated Herpesvirus-Positive Primary Effusion Lymphoma With Expression of the CD138/Syndecan-1 Antigen

Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) [see comments]

Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis

Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin‧s lymphoma

BCR-ABL breakpoint and prognosis in chronic myeloid leukemia [letter; comment]

New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia

Alternative BCR/ABL transcripts in chronic myeloid leukemia [letter; comment]

Molecular characterization of hereditary persistence of fetal hemoglobin in a patient from Cuba [letter]

Prenatal diagnosis of fetal hemoglobin Lepore-Boston disease on maternal peripheral blood

A new hereditary persistence of fetal hemoglobin deletion has the breakpoint within the 3' beta-globin gene enhancer

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only